x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The IMID Forum

The Immune-Mediated Inflammatory Disease Forum

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

education

All Episodes

00:10:24

Discussing Rheumatology: November 2022

The IMID Forum ·

2022/11/24

Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs

en

00:24:11

Discussing PsA: Episode 4

The IMID Forum ·

2022/11/09

Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in

en

00:13:25

Discussing Rheumatology: October 2022

The IMID Forum ·

2022/10/28

Discussing Rheumatology: October 2022 by The IMID Forum

en

00:22:03

Discussing AxSpA: Episode 3

The IMID Forum ·

2022/10/12

Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of

en

00:12:51

Discussing Rheumatology: September 2022

The IMID Forum ·

2022/09/28

Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed

en

00:30:40

Author Interview: Eduardo Mysler

The IMID Forum ·

2022/09/28

Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'

en

00:37:10

Discussing PsA: Episode 3

The IMID Forum ·

2022/09/13

Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other

en

00:21:14

Author Interview: Ameen Jubber

The IMID Forum ·

2022/08/22

Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.

en

00:08:15

CSF Monthly Podcast August22

The IMID Forum ·

2022/08/22

Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

en

00:21:02

Author Interview: Kim Lauper

The IMID Forum ·

2022/08/10

Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’

en

00:22:04

Discussing AxSpA: Episode 2

The IMID Forum ·

2022/08/08

Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in

en

00:09:42

Discussing Rheumatology: July 2022

The IMID Forum ·

2022/07/28

Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide

en

00:26:39

Discussing PsA: Episode 2

The IMID Forum ·

2022/07/27

Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients

en

00:17:20

Author Interview: Diego Kyburz

The IMID Forum ·

2022/07/25

Author Interview: Diego Kyburz by The IMID Forum

en

00:08:45

Discussing Rheumatology: June 2022

The IMID Forum ·

2022/07/18

Discussing Rheumatology: June 2022 by The IMID Forum

en

00:18:41

Discussing axSpA: Episode 1

The IMID Forum ·

2022/06/24

Discussing axSpA: Episode 1 by The IMID Forum

en

00:29:59

Discussing PsA: Episode 1

The IMID Forum ·

2022/06/07

Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus

en

00:18:59

DAY 4: EULAR 2022 Daily Highlights

The IMID Forum ·

2022/06/04

Douglas Veale takes you through our top picks from the selection of abstracts presented at the final day of EULAR 2022 (Saturday 4 June). Today's podcast covers RA, PsA, and axSpA.

en

00:28:15

DAY 3: EULAR 2022 Daily Highlights

The IMID Forum ·

2022/06/03

Douglas Veale takes you through our top picks from the selection of abstracts at EULAR 2022 today (Friday 3 June). Today's podcast covers RA, PsA, and axSpA.

en

00:06:17

DAY 2: EULAR 2022 Daily Highlights

The IMID Forum ·

2022/06/02

Laura Coates takes you through our top picks from the selection of abstracts at EULAR 2022 today (Thursday 2 June). Today's podcast covers RA, PsA, and axSpA.

en

387 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College